KERYX BIOPHARMACEUTICALS INC — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/133876eb-d2eb-4dcf-9e61-b193a69daab4/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2017 | $-101.7M | 2017-01-01 – 2017-12-31 | evidence 0001114220-18-000029 |
| FY 2016 | $-122.8M | 2016-01-01 – 2016-12-31 | evidence 0001114220-17-000006 |
| FY 2015 | $-111.1M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-481950 |
| FY 2014 | $-111.2M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-069937 |
| FY 2013 | $-47.1M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-097931 |
| FY 2012 | $-27.1M | 2012-01-01 – 2012-12-31 | evidence 0001144204-13-014537 |
| FY 2011 | $-28.7M | 2011-01-01 – 2011-12-31 | evidence 0001144204-12-012714 |
| FY 2010 | $-21.2M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-012714 |
| FY 2009 | $9.8M | 2009-01-01 – 2009-12-31 | evidence 0001144204-12-012714 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
KERYX BIOPHARMACEUTICALS INC — all facts · Revenue · Net Income